01 / 01

RESEARCH & INNOVATION

Dementia & Alzheimer’s Disease : a worldwide public health issue

Towards an innovative and cutting-edge therapy for Alzheimer’s disease

 The RGn530 device has shown highly significant and valuable results in in preclinical studies performed on an Alzheimer’s disease animal model.

REGEnLIFE has defined a unique application protocol for its neurophotonic treatment.

The RGn530 device A unique neurological device

The RGn530 device is currently the only medical technology that takes into account the emerging hypothesis for pathogenic factors of neurodegenerative diseases.

The photonic device acts both on inflammation and at a mitochondria level. Therefore, it represents a serious therapeutic approach to treat these neurological disorders.

The RGn530 device, designed in a unique manner to operate both on the head and abdomen, takes also in consideration the influence of peripheral inflammation and microbiota in these diseases. The smart combination of multiple targets appears today to be essential to treat these very complex neurodegenerative disorders.

Scientific
publications

Scientific Articles

Blivet Guillaume, Johann Meunier, Francois J. Roman, Jacques Touchon. Neuroprotective effect of a new photobiomodulation technique against amyloid Aβ25-35 peptide induced toxicity in mice: novel hypothesis for therapeutic approach of Alzheimer’s disease suggested. 2018. Alzheimer’s & Dementia: Translational Research & Clinical Interventions

Oral Communications

  • CTAD 2017 (Clinical Trials on Alzheimer’s Disease)

Neuroprotective Effect of a New Photobiomodulation Technique against Amyloid Aβ25- 35 Peptide-Induced Toxicity in Mice. Guillaume J. Blivet, Johann Meunier, Francois J. Roman, Jacques Touchon.

  • CTAD 2017 – Highlights

Thinking outside the box

  • CTAD 2018

The  neuroprotective  effect  of  a  new  photobiomodulation  technique  on  Aβ25-35 peptide-induced toxicity dramatically impact gut microbiota dysbiosis.  Laura Auboyer, Johann  Meunier, Laura Ceolin, François  J.  Roman, Rémy Burcelin, Guillaume J. Blivet, Jacques  Touchon.

Posters

  • AAT-ADPD 2018 (Advances in Alzheimer’s and Parkinson’s Therapies)

Neuroprotective effect of a new photo-biomodulation technique against amyloid Aβ25-35 peptide induced toxicity in mice might support : a novel hypothesis for therapeutic approach of Alzheimer’s disease. Guillaume J. Blivet, Johann Meunier, Francois J. Roman, Jacques Touchon.

  • CTAD 2018

Neuroprotective effect of a new photobiomodulation technique against amyloid Aβ25-35 peptide induced  toxicity in mice might support a novel hypothesis for therapeutic approach of Alzheimer’s disease. Guillaume J. Blivet, Laura Auboyer, Johann Meunier, François J. Roman, Jacques Touchon.

Interest of REGEnLIFE RGn530 photobiomodulation medical device for the treatment of Alzheimer’s disease:  a double-blind, randomized sham-controlled trial to evaluate the safety and efficacy. Audrey Gabelle, Thibault Mura, Karim Bennys, Sophie Navucet, Martine Flores, Laura Auboyer, Guillaume J. Blivet, Jacques Touchon.